The RIDASCREEN® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) in human serum and plasma.
Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α4β7-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab.
The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets.
- CE-marked version of the ELISA tests of KU Leuven
- Highly specific antibodies
- Ready to use reagents
- Validated for use on automated ELISA systems, e.g. the Dynex DSX®
|Microtiter plate with 96 wells (12 strips with 8 removable wells each)
|1 h 40 min
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.